NewAmsterdam Pharma Co N.V.
NAMSW· Nasdaq
Released Aug 6, 2025, before the open
10-Q filed Aug 6, 2025, 37 days after period end · 0000950170-25-103521
| Metric | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|
| Revenue | $19.15M | $2.28M | $1.72M |
| Net Income | -$17.36M | -$39.01M | -$38.29M |
| EPS Diluted | -$0.15 | -$0.41 | -$0.47 |
NewAmsterdam Pharma Co N.V. · CIK 1936258 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.